New Jersey Kidney Care, LLC

Frenova Renal Research

Kidney Diseases

IGA Glomerulonephritis

Proteinuria

Chronic Renal Insufficiency

LNP023

ANG-3070

BI 685509

Angion

Boehringer Ingelheim

Novartis

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Frenova Renal Research | New Jersey Kidney Care, LLC

Site insights

Work at this site?

Active trials

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)

Trial sponsors